World Alzheimer's Day 2021: The Power of Knowledge

World Alzheimer's Day is an international campaign organised by Alzheimer's Disease International to raise awareness and highlight issues faced by people affected by dementia. It takes place every year on September 21st and is the focus of World Alzheimer's Month.

Dementia is one of the biggest challenges we face, with nearly 50 million people living with dementia worldwide. Yet 2 out of every 3 people globally believe there is little or no understanding of dementia in their countries.The impact of World Alzheimer's Month is growing, but the stigmatisation and misinformation that surrounds dementia remains a global problem. To tackle this challenge, we need to collaborate and share best practice with one another.

In support of this year’s theme – ‘Know dementia, know Alzheimer's’ - Elsevier presents a curated, open access collection of over 70 journal articles and book chapters focused on shining a light on the warning signs of dementia and the importance of a timely diagnosis.

Elsevier,

Archives of Gerontology and Geriatrics, Volume 89, July - August 2020

Vision, executive function and balance is worse with age and dementia. Executive function mediates the relationship between vision and balance. Poor vision is related to poor executive function. Poor executive function is related to poor balance control. Older adult clinical tests should examine vision, balance and executive function.
Elsevier,

Steroids, Volume 156, April 2020

These data suggest that vitamin D analogue, Maxacalcitol could be used as a therapeutic agent in treatment of Alzheimer disease.
Elsevier,

Public Health, Volume 181, April 2020

Research on helping to maintain a personal and social identity for people with Alzheimer's Disease. Results suggest further interventions that might be able to promote continuity maintenance.
Elsevier,

Journal for Nurse Practitioners, Volume 16, March 2020

Alzheimer’s disease (AD) is the most common neurodegenerative disease that causes cognitive decline. Drugs under development focus on disease-modifying therapies, symptomatic cognitive enhancers, and agents addressing neuropsychiatric changes. Biomarkers in cerebrospinal fluid and positron emission scans will enable clinicians and researchers to identify AD much earlier.
Elsevier,

Peptides, Volume 125, March 2020

GIP is a hormone and a growth factor that plays key roles in the brain. Protease-resistant GIP analogues show neuroprotective effects in animal models. Cognition and synaptic plasticity is protected in animal models of Alzheimer’s disease. Neuronal energy utilisation, cell repair and mitochondrial function is protected. Motor activity and dopaminergic neuronal function is protected in models of Parkinson’s disease.
Elsevier,

Journal of the American Academy of Dermatology, Volume 82, February 2020

Caffeinated coffee and crude caffine extract, a by-product of the coffee decaffeination process, contains a variety of noncaffeine metabolites, including anti-inflammatory phytochemicals. These molecules were propsed as an explanation for why crude caffeine extract, but not pure caffeine, provided therapeutic benefit in a mouse model of Alzheimers disease.
Elsevier,

Dementia Rehabilitation, October 2020, Pages 227-261

This book chapter advances SDGs 3 and 17 by reviewing research on a range of rehabilitation programmes aiming to improve the functional independence of people with dementia, such as specialist-led or multimodal rehabilitation, cognitive rehabilitation, function-focused care, and reablement.
Elsevier,

Dementia Rehabilitation, October 2021, Pages 57-79

This book chapter advances SDGs 3 and 17 by outlining the common physical impairments found in people living with dementia, as well as evidence for treatments to maintain or improve physical function and prevent falls, in both community and residential settings.
Elsevier,

Dementia Rehabilitation, October 2020, Pages 35-56

This book chapter advances SDGs 3 and 17 by reviewing behavioral interventions and strategies for spoken communication for people with dementia and their communication partners.
Elsevier,

Diagnosis and Management in Dementia, Volume 1, August 2020, Pages 681-693

This book chapter advances SDGs 3 and 17 by reviewing pathological and functional outcomes of both preventative and therapeutic environmental enrichment on commonly used mouse models of amyloid pathology.

Pages